MET and neoplasm: Tsuta et al. described more divergent findings compared to our study cohort reporting amplification of the MET gene in 10,9% of NSCLC cases assessed by BISH (bright-field in situ hybridization, BISH-positive, when one of five criteria were met, for example: MET to CEN7 ratio ≥2.0 or >15.0 copies of the MET signal in >10% of tumor cells) [36].